Frank De Smet
Research Subjects
Frank De Smet has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Nathalie Pochet
Broad Institute
10 shared publications Bart De Moor
STADIUS Center for Dynamical Systems (M.Cl., B.D.M.), KU Leuven, B-3000 Leuven, Belgium 2 Signal Processing and Data Analytics, Department of Electrical Engineering, iMinds Medical IT, (M.Cl., B.D.M.), KU Leuven, B-3000 Leuven, Belgium
9 shared publicationsB. De Moor
7 shared publications- Frédéric Amant
Department of oncology, KU Leuven, Leuven, Belgium
6 shared publications - Kathleen Marchal
Department of Plant Biotechnology and Bioinformatics, Ghent University , Ghent 9052
6 shared publications - Olivier Gevaert
Department of Biomedical Data Science Stanford University 94305 Stanford CA USA
6 shared publications
Latest Publications
- 1 November 2020
- Published by Elsevier in Environmental Pollution
- Vol. 266, 115130
Antithrombotic medication and endovascular interventions associated with short-term exposure to particulate air pollution: A nationwide case-crossover study
- 1 November 2020
- Published by Elsevier in Environmental Pollution
- Vol. 266, 115130
Antithrombotic medication and endovascular interventions associated with short-term exposure to particulate air pollution: A nationwide case-crossover study
- Open Access
- 1 February 2016
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 101 (2) , 461-469
Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study
Context: Several observational studies and meta-analyses have reported increased mortality of patients taking sulfonylurea and insulin. The impact of patient profiles and concomitant therapies often remains unclear. Objective: The objective of the study was to quantify survival of patients after starting glucose-lowering agents (GLAs) and compare it with control subjects, matched for risk profiles and concomitant therapies. Design: This was a retrospective, controlled, cohort study. Setting: The study is based on health expenditure records of the largest Belgian health mutual insurer, covering more than 4.4 million people. Patients: A total of 115 896 patients starting metformin, sulfonylurea, or insulin (alone or in combination) between January 2003 and December 2007 participated in the study. Control subjects without GLA therapy were matched for age, gender, history of cardiovascular events, and therapy with antihypertensives, statins and blood platelet aggregation inhibitors. Intervention(s): There were no interventions. Main Outcome Measure: Five-year survival after the start of GLA was measured. Results: Profiles of patients using different GLAs varied, with patients on sulfonylurea being oldest and patients on insulin having more frequently a history of cardiovascular disease. Excess mortality differed across GLA therapies compared with matched controls without GLAs, even after adjusting for observable characteristics. Only metformin monotherapy was not associated with an increased 5-year mortality compared with matched controls, whereas individuals on a combination of sulfonylurea and insulin had the highest mortality risks. Age and concomitant use of statins strongly affect survival. Conclusions: Differences exist in 5-year survival of patients on GLA, at least partly driven by the risk profile of the individuals themselves. Metformin use was associated with lowest 5-year mortality risk and statins dramatically lowered 5-year mortality throughout all cohorts.
- 1 February 2016
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 101 (2) , 461-469
Open AccessMortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study
Context: Several observational studies and meta-analyses have reported increased mortality of patients taking sulfonylurea and insulin. The impact of patient profiles and concomitant therapies often remains unclear. Objective: The objective of the study was to quantify survival of patients after starting glucose-lowering agents (GLAs) and compare it with control subjects, matched for risk profiles and concomitant therapies. Design: This was a retrospective, controlled, cohort study. Setting: The study is based on health expenditure records of the largest Belgian health mutual insurer, covering more than 4.4 million people. Patients: A total of 115 896 patients starting metformin, sulfonylurea, or insulin (alone or in combination) between January 2003 and December 2007 participated in the study. Control subjects without GLA therapy were matched for age, gender, history of cardiovascular events, and therapy with antihypertensives, statins and blood platelet aggregation inhibitors. Intervention(s): There were no interventions. Main Outcome Measure: Five-year survival after the start of GLA was measured. Results: Profiles of patients using different GLAs varied, with patients on sulfonylurea being oldest and patients on insulin having more frequently a history of cardiovascular disease. Excess mortality differed across GLA therapies compared with matched controls without GLAs, even after adjusting for observable characteristics. Only metformin monotherapy was not associated with an increased 5-year mortality compared with matched controls, whereas individuals on a combination of sulfonylurea and insulin had the highest mortality risks. Age and concomitant use of statins strongly affect survival. Conclusions: Differences exist in 5-year survival of patients on GLA, at least partly driven by the risk profile of the individuals themselves. Metformin use was associated with lowest 5-year mortality risk and statins dramatically lowered 5-year mortality throughout all cohorts.
- Open Access
- 21 December 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 18585
Did Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium?
Vaccination can place selective pressures on viral populations, leading to changes in the distribution of strains as viruses evolve to escape immunity from the vaccine. Vaccine-driven strain replacement is a major concern after nationwide rotavirus vaccine introductions. However, the distribution of the predominant rotavirus genotypes varies from year to year in the absence of vaccination, making it difficult to determine what changes can be attributed to the vaccines. To gain insight in the underlying dynamics driving changes in the rotavirus population, we fitted a hierarchy of mathematical models to national and local genotype-specific hospitalization data from Belgium, where large-scale vaccination was introduced in 2006. We estimated that natural- and vaccine-derived immunity was strongest against completely homotypic strains and weakest against fully heterotypic strains, with an intermediate immunity amongst partially heterotypic strains. The predominance of G2P[4] infections in Belgium after vaccine introduction can be explained by a combination of natural genotype fluctuations and weaker natural and vaccine-induced immunity against infection with strains heterotypic to the vaccine, in the absence of significant variation in strain-specific vaccine effectiveness against disease. However, the incidence of rotavirus gastroenteritis is predicted to remain low despite vaccine-driven changes in the distribution of genotypes.
- 21 December 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 18585
Open AccessDid Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium?
Vaccination can place selective pressures on viral populations, leading to changes in the distribution of strains as viruses evolve to escape immunity from the vaccine. Vaccine-driven strain replacement is a major concern after nationwide rotavirus vaccine introductions. However, the distribution of the predominant rotavirus genotypes varies from year to year in the absence of vaccination, making it difficult to determine what changes can be attributed to the vaccines. To gain insight in the underlying dynamics driving changes in the rotavirus population, we fitted a hierarchy of mathematical models to national and local genotype-specific hospitalization data from Belgium, where large-scale vaccination was introduced in 2006. We estimated that natural- and vaccine-derived immunity was strongest against completely homotypic strains and weakest against fully heterotypic strains, with an intermediate immunity amongst partially heterotypic strains. The predominance of G2P[4] infections in Belgium after vaccine introduction can be explained by a combination of natural genotype fluctuations and weaker natural and vaccine-induced immunity against infection with strains heterotypic to the vaccine, in the absence of significant variation in strain-specific vaccine effectiveness against disease. However, the incidence of rotavirus gastroenteritis is predicted to remain low despite vaccine-driven changes in the distribution of genotypes.
- Open Access
- 20 November 2015
- Published by Oxford University Press (OUP) in International Journal for Quality in Health Care
- Vol. 28 (1) , 22-32
Community-acquired pneumonia (CAP) hospitalizations and deaths: is there a role for quality improvement through inter-hospital comparisons?
To assess between-hospital variations in standardized in-hospital mortality ratios of community-acquired pneumonia (CAP), and identify possible leads for quality improvement. We used an administrative database to estimate standardized in-hospital mortality ratios for 111 Belgian hospitals, by carrying out a set of hierarchical logistic regression models, intended to disentangle therapeutic attitudes and biases. To facilitate the detection of false-negative/positive results, we added an inconclusive zone to the funnel plots, derived from the results of the study. Data quality was validated by comparison with (i) alternative data from the largest Belgian Sickness Fund, (ii) published German hospital data and (iii) the results of an on-site audit. All Belgian hospital discharge records from 2004 to 2007. A total of 111 776 adult patients were admitted for CAP. Risk-adjusted standardized in-hospital mortality ratios. Out of the 111 hospitals, we identified five and six outlying hospitals, with standardized mortality ratios of CAP consistently on the extremes of the distribution, as providing possibly better or worse care, respectively, and 18 other hospitals as having possible quality weaknesses/strengths. At the individuals' level of the analysis, adjusted odds ratios showed the paramount importance of old age, comorbidity and mechanical ventilation. The data compared well with the different validation sources. Despite the limitations inherent to administrative data, it seemed possible to establish inter-hospital differences in standardized in-hospital mortality ratios of CAP and to identify leads for quality improvement. Monitoring is needed to assess progress in quality.
- 20 November 2015
- Published by Oxford University Press (OUP) in International Journal for Quality in Health Care
- Vol. 28 (1) , 22-32
Open AccessCommunity-acquired pneumonia (CAP) hospitalizations and deaths: is there a role for quality improvement through inter-hospital comparisons?
To assess between-hospital variations in standardized in-hospital mortality ratios of community-acquired pneumonia (CAP), and identify possible leads for quality improvement. We used an administrative database to estimate standardized in-hospital mortality ratios for 111 Belgian hospitals, by carrying out a set of hierarchical logistic regression models, intended to disentangle therapeutic attitudes and biases. To facilitate the detection of false-negative/positive results, we added an inconclusive zone to the funnel plots, derived from the results of the study. Data quality was validated by comparison with (i) alternative data from the largest Belgian Sickness Fund, (ii) published German hospital data and (iii) the results of an on-site audit. All Belgian hospital discharge records from 2004 to 2007. A total of 111 776 adult patients were admitted for CAP. Risk-adjusted standardized in-hospital mortality ratios. Out of the 111 hospitals, we identified five and six outlying hospitals, with standardized mortality ratios of CAP consistently on the extremes of the distribution, as providing possibly better or worse care, respectively, and 18 other hospitals as having possible quality weaknesses/strengths. At the individuals' level of the analysis, adjusted odds ratios showed the paramount importance of old age, comorbidity and mechanical ventilation. The data compared well with the different validation sources. Despite the limitations inherent to administrative data, it seemed possible to establish inter-hospital differences in standardized in-hospital mortality ratios of CAP and to identify leads for quality improvement. Monitoring is needed to assess progress in quality.
- Open Access
Building Classifiers to Predict the Start of Glucose-Lowering Pharmacotherapy Using Belgian Health Expenditure Data
Early diagnosis is important for type 2 diabetes (T2D) to improve patient prognosis, prevent complications and reduce long-term treatment costs. We present a novel risk profiling approach based exclusively on health expenditure data that is available to Belgian mutual health insurers. We used expenditure data related to drug purchases and medical provisions to construct models that predict whether a patient will start glucose-lowering pharmacotherapy in the coming years, based on that patient's recent medical expenditure history. The design and implementation of the modeling strategy are discussed in detail and several learning methods are benchmarked for our application. Our best performing model obtains between 74.9% and 76.8% area under the ROC curve, which is comparable to state-of-the-art risk prediction approaches for T2D based on questionnaires. In contrast to other methods, our approach can be implemented on a population-wide scale at virtually no extra operational cost. Possibly, our approach can be further improved by additional information about some risk factors of T2D that is unavailable in health expenditure data.
Open AccessBuilding Classifiers to Predict the Start of Glucose-Lowering Pharmacotherapy Using Belgian Health Expenditure Data
Early diagnosis is important for type 2 diabetes (T2D) to improve patient prognosis, prevent complications and reduce long-term treatment costs. We present a novel risk profiling approach based exclusively on health expenditure data that is available to Belgian mutual health insurers. We used expenditure data related to drug purchases and medical provisions to construct models that predict whether a patient will start glucose-lowering pharmacotherapy in the coming years, based on that patient's recent medical expenditure history. The design and implementation of the modeling strategy are discussed in detail and several learning methods are benchmarked for our application. Our best performing model obtains between 74.9% and 76.8% area under the ROC curve, which is comparable to state-of-the-art risk prediction approaches for T2D based on questionnaires. In contrast to other methods, our approach can be implemented on a population-wide scale at virtually no extra operational cost. Possibly, our approach can be further improved by additional information about some risk factors of T2D that is unavailable in health expenditure data.
- 14 March 2015
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 17 (3) , 305-315
The impact of non-financial and financial encouragements on participation in non school-based human papillomavirus vaccination: a retrospective cohort study
Adolescent vaccination coverage under a system of non school-based vaccination is likely to be suboptimal, but might be increased by targeted encouragement campaigns. We analysed the effect on human papillomavirus (HPV) vaccination initiation by girls aged 12–18 of two campaigns set up in Flanders (Belgium) in 2007 and 2009: a personal information campaign and a combined personal information and financial incentive campaign. We analysed (objective) data on HPV vaccination behaviour from the National Alliance of Christian Mutualities (NACM), Flanders’ largest sickness fund. We used z-scores to compare the monthly proportion of girls initiating HPV vaccination over time between carefully selected intervention and control groups. Separate analyses were done for older and younger girls. Total sample sizes of the intervention (control) groups were 221 (243) for the personal information campaign and 629 (5,322) for the combined personal information and financial incentive campaign. The personal information campaign significantly increased vaccination initiation, with older girls reacting faster. One year after the campaign the percentages of vaccination initiation for the oldest girls were 64.6 and 42.8 % in the intervention and control group, respectively (z = 3.35, p = 0.0008); for the youngest girls the percentages were 78.4 and 68.1 % (z = 1.71, p = 0.09). The combined personal information and financial incentive campaign increased vaccination initiation among certain age groups. One year after the campaign the difference in percentage points for HPV vaccination initiation between intervention and control groups varied between 18.5 % (z = 3.65, p = 0.0002) and 5.1 % (z = 1.12, p = 0.26). Under a non school-based vaccination system, personal information and removing out-of-pocket costs had a significant positive effect on HPV vaccination initiation, although the effect substantially varied in magnitude. Overall, the obtained vaccination rates remained far below those realised under school-based HPV vaccination.
- 14 March 2015
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 17 (3) , 305-315
The impact of non-financial and financial encouragements on participation in non school-based human papillomavirus vaccination: a retrospective cohort study
Adolescent vaccination coverage under a system of non school-based vaccination is likely to be suboptimal, but might be increased by targeted encouragement campaigns. We analysed the effect on human papillomavirus (HPV) vaccination initiation by girls aged 12–18 of two campaigns set up in Flanders (Belgium) in 2007 and 2009: a personal information campaign and a combined personal information and financial incentive campaign. We analysed (objective) data on HPV vaccination behaviour from the National Alliance of Christian Mutualities (NACM), Flanders’ largest sickness fund. We used z-scores to compare the monthly proportion of girls initiating HPV vaccination over time between carefully selected intervention and control groups. Separate analyses were done for older and younger girls. Total sample sizes of the intervention (control) groups were 221 (243) for the personal information campaign and 629 (5,322) for the combined personal information and financial incentive campaign. The personal information campaign significantly increased vaccination initiation, with older girls reacting faster. One year after the campaign the percentages of vaccination initiation for the oldest girls were 64.6 and 42.8 % in the intervention and control group, respectively (z = 3.35, p = 0.0008); for the youngest girls the percentages were 78.4 and 68.1 % (z = 1.71, p = 0.09). The combined personal information and financial incentive campaign increased vaccination initiation among certain age groups. One year after the campaign the difference in percentage points for HPV vaccination initiation between intervention and control groups varied between 18.5 % (z = 3.65, p = 0.0002) and 5.1 % (z = 1.12, p = 0.26). Under a non school-based vaccination system, personal information and removing out-of-pocket costs had a significant positive effect on HPV vaccination initiation, although the effect substantially varied in magnitude. Overall, the obtained vaccination rates remained far below those realised under school-based HPV vaccination.
- Open Access
A Robust Ensemble Approach to Learn From Positive and Unlabeled Data Using SVM Base Models
We present a novel approach to learn binary classifiers when only positive and unlabeled instances are available (PU learning). This problem is routinely cast as a supervised task with label noise in the negative set. We use an ensemble of SVM models trained on bootstrap resamples of the training data for increased robustness against label noise. The approach can be considered in a bagging framework which provides an intuitive explanation for its mechanics in a semi-supervised setting. We compared our method to state-of-the-art approaches in simulations using multiple public benchmark data sets. The included benchmark comprises three settings with increasing label noise: (i) fully supervised, (ii) PU learning and (iii) PU learning with false positives. Our approach shows a marginal improvement over existing methods in the second setting and a significant improvement in the third.
Open AccessA Robust Ensemble Approach to Learn From Positive and Unlabeled Data Using SVM Base Models
We present a novel approach to learn binary classifiers when only positive and unlabeled instances are available (PU learning). This problem is routinely cast as a supervised task with label noise in the negative set. We use an ensemble of SVM models trained on bootstrap resamples of the training data for increased robustness against label noise. The approach can be considered in a bagging framework which provides an intuitive explanation for its mechanics in a semi-supervised setting. We compared our method to state-of-the-art approaches in simulations using multiple public benchmark data sets. The included benchmark comprises three settings with increasing label noise: (i) fully supervised, (ii) PU learning and (iii) PU learning with false positives. Our approach shows a marginal improvement over existing methods in the second setting and a significant improvement in the third.
- Open Access
EnsembleSVM: A Library for Ensemble Learning Using Support Vector Machines
EnsembleSVM is a free software package containing efficient routines to perform ensemble learning with support vector machine (SVM) base models. It currently offers ensemble methods based on binary SVM models. Our implementation avoids duplicate storage and evaluation of support vectors which are shared between constituent models. Experimental results show that using ensemble approaches can drastically reduce training complexity while maintaining high predictive accuracy. The EnsembleSVM software package is freely available online at http://esat.kuleuven.be/stadius/ensemblesvm.
Open AccessEnsembleSVM: A Library for Ensemble Learning Using Support Vector Machines
EnsembleSVM is a free software package containing efficient routines to perform ensemble learning with support vector machine (SVM) base models. It currently offers ensemble methods based on binary SVM models. Our implementation avoids duplicate storage and evaluation of support vectors which are shared between constituent models. Experimental results show that using ensemble approaches can drastically reduce training complexity while maintaining high predictive accuracy. The EnsembleSVM software package is freely available online at http://esat.kuleuven.be/stadius/ensemblesvm.
- Open Access
- 1 January 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 39
The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease
Haemophilia is a rare hereditary haemorrhagic disease that requires regular intravenous injections of clotting factor (CF) concentrates. This study sought to estimate the health and economic burden of haemophilia in Belgium. This is the first study of its type to be conducted, and reflects the Belgian authorities’ growing interest for haemophilia as part of their priority planning for rare and chronic diseases.
- 1 January 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 39
Open AccessThe health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease
Haemophilia is a rare hereditary haemorrhagic disease that requires regular intravenous injections of clotting factor (CF) concentrates. This study sought to estimate the health and economic burden of haemophilia in Belgium. This is the first study of its type to be conducted, and reflects the Belgian authorities’ growing interest for haemophilia as part of their priority planning for rare and chronic diseases.